login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Amgen's Xgeva to be Probed by FDA Panel
The FDA said that while Xgeva does manage to slow down the progress of prostate cancer into the bone, there was no evidence that it increased the lifespan of the patients. Moreover the drug has been known to be associated with serious side effects including the risk of bone disease, which occurred in 5 percent of the patients who took the drug.
With Amgen applying for approval of Xgeva for treating prostate cancer, the FDA will be seeking advice from a panel of outside experts with regards to the drug’s benefits. ISI Group analyst Mark Schoenebaum said that the agency’s negative review of Xgeva was to be expected since the FDA has previously asked whether just delaying the spread of cancer to the bone should be considered as a real benefit.
“As was generally expected by us and much of the Street, the FDA is critical of the data, questioning the clinical meaningfulness of the primary endpoint”, Schoenebaum said.
Source-Medindia
|
|
 Comment & Contribute
|
Medwonders Health Network
- Health News Index
|
|
- News Quick Links
| News Categories: |
| » | Mystery of 'Disappearing' Tweets Solved |
| » | 'Slut Walks' Attract Thousands in Brazil |
| » | Enthusiasm for Tattoos High Among Women |
| » | Individuals' Brains 'Tick Together' If They Have Strong Emotions |
| » | Keeping Emotions in Check and Being Resilient Helps to Remain Satisfied With Life |
| More Life Style News | |
|
